Dori Thomas-Karyat
Founder & Chief Executive Officer Synthis Therapeutics, Inc
Dr. Dori Thomas-Karyat is the Founder and CEO of Synthis Therapeutics, where she leads the development of a first-in-class ADC platform targeting TGF-ß-driven diseases, including fibrotic disorders such as IPF. A recognized expert in TGF-ß biology with over 20 years of experience in oncology, fibrosis, and immuno-oncology, she has held leadership roles in drug discovery at AbbVie and Roche. Dr. Thomas-Karyat completed her postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in the lab of TGF-ß pioneer Dr. Joan Massagué and holds a Ph.D. in Immunology from Washington University School of Medicine in St. Louis. She has been awarded multiple SBIR grants, holds six issued patents, and is a frequent speaker at scientific conferences.
Seminars
- Developed first in class non-cytotoxic, linkable TGF-b inhibitor payload to selectively and safely block TGF-b, in an Antibody drug conjugate format
- SYN101 is a first in class immune cell targeted TGF-b therapy that restores immune function in cancer patients
- SYN303 is a myofibroblast targeted TGF-b therapy that blocks fibrosis and inflammation in a wide variety of fibrotic diseases
